Is United Therapeutics Corporation (UTHR) overvalued? · P/E 20, rev $2.88B
United Therapeutics Corporation (UTHR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page asks whether United Therapeutics Corporation (UTHR) looks expensive on cached numbers — not a short thesis.
Latest reported UTHR revenue for 2024-12-31 was $2.88B. Net income was $1.20B. Revenue was up 23.6% from 2023-12-31 to 2024-12-31. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
UTHR currently screens at market cap $23.41B and trailing P/E 20.4. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next UTHR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the UTHR stock page for the full model, not this heading.
Not investment advice.